ElevateBio Raises $401m To Fund Its Own And Partners’ Future Cell And Gene Therapy Needs
$1.3bn Invested In R&D, Manufacturing One-Stop Shop To Date
ElevateBio closed a series D venture capital round and revealed a potentially multibillion-dollar deal between its Life Edit subsidiary and Novo Nordisk as demand for its cell and gene therapy capabilities grow.
